(Reuters) - Last month, India's Sun Pharma agreed to buy Taro Pharmaceutical Industries for $7.75 per share or $230 million with an additional $224 million to refinance Taro's debt.
Franklin Advisers Inc. and Templeton Assets Management Ltd., which own 9 percent of Taro, filed a case in a Tel Aviv court, seeking to restrain Taro from concluding any deal that could hurt minority interests. But the court decided not to issue a temporary injunction against the deal.
Read more at Reuters.com Mergers News
Franklin Advisers Inc. and Templeton Assets Management Ltd., which own 9 percent of Taro, filed a case in a Tel Aviv court, seeking to restrain Taro from concluding any deal that could hurt minority interests. But the court decided not to issue a temporary injunction against the deal.
Read more at Reuters.com Mergers News
No comments:
Post a Comment